Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;16(6):1038-1043.
doi: 10.1177/1533034617722080. Epub 2017 Aug 2.

Drug-Eluting Biopsy Needle as a Novel Strategy for Antimicrobial Prophylaxis in Transrectal Prostate Biopsy

Marcin Sieczkowski  1 , Artur Gibas  1 , Andrzej Wasik  2 , Agata Kot-Wasik  2 , Lidia Piechowicz  3 , Jacek Namieśnik  2 , Marcin Matuszewski  1
Affiliations

Drug-Eluting Biopsy Needle as a Novel Strategy for Antimicrobial Prophylaxis in Transrectal Prostate Biopsy

Marcin Sieczkowski et al. Technol Cancer Res Treat. 2017 Dec.

Abstract

Objectives: To preclinically evaluate drug-eluting biopsy needles (patent pending WO2016118026) as a new potential way of antimicrobial prophylaxis for transrectal prostate biopsy.

Methods: Twenty steel biopsy needles have been coated with polyvinyl alcohol, ciprofloxacin, and amikacin. Modified biopsy needles have been randomly divided into 3 groups (1:2:1 ratio). Needles from group I were immersed for 30 minutes in dedicated test tubes containing saline. Needles from group II were immersed (one by one) for 5 seconds in a set of 12 test tubes containing saline. Then, each solution was analyzed using high-performance liquid chromatography. The results were compared with the susceptibility break points for Escherichia coli. Group III was incubated with E coli strains on Mueller-Hinton plate and then the bacterial inhibition zones surrounding needles were measured.

Results: The average concentration of antibiotics eluted from needles (group I) was 361.98 ± 15.36 µg/mL for amikacin and 63.87 ± 5.95 µg/mL for ciprofloxacin. The chromatographic analysis revealed the gradual release of both antibiotics from needles (group II). The concentration of amikacin released from needles exceeded the break-point value from first to ninth immersion. Ciprofloxacin concentration was higher than break-point value in all immersions. The average bacterial inhibition zone minor axis was 42 ± 5.7 mm (group III).

Conclusions: The use of drug-eluting biopsy needle could be a new potential way of antimicrobial prophylaxis for transrectal prostate biopsy. This study confirmed its biological activity as well as the gradual release of antibiotics from its surface. Confirmation of its preventive role, in terms of infectious complications after transrectal prostate biopsy, has to be evaluated in a clinical trial.

Keywords: Escherichia coli; antibiotic prophylaxis; biopsy needle; prostate biopsy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Coating method repeatability test (group I).
Figure 2.
Figure 2.
Injection simulation test (group II).
Figure 3.
Figure 3.
Escherichia coli inhibition zone around part of drug-eluting biopsy needle (DEBN) coated with an antimicrobial layer (group III).
See this image and copyright information in PMC

References

    1. Mottet N, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. 2014;65(1):124–137. - PubMed
    1. Liss MA, Chang A, Santos R, et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol. 2011;185(4):1283–1288. - PMC - PubMed
    1. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830–1834. - PMC - PubMed
    1. Gonzalez C, Averch T, Boyd L, et al. AUA/SUNA White Paper on the incidence, prevention and treatment of complications related to prostate needle biopsy. AUA White Paper. American Urological Association; 2012. https://www.suna.org/resources/pnbWhitePaper.pdf. Accessed July 23, 2017.
    1. Crawford ED, Haynes AL, Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol. 1982;127(3):449–451. - PubMed